Addition of Dostarlimab to Chemotherapy Represents New Standard of Care in Endometrial Cancer
New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.
Deep Responses, Exciting Data: Botensilimab/Balstilimab Combo in Ovarian Cancer
Phase 1 data signals promise for botensilimab plus bastilimab for advanced ovarian cancer.
Toripalimab, Bevacizumab, and Chemo Elicits Responses in Refractory, Recurrent, or Metastatic Cervical Cancer
Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.
Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
Bruno Bockorny, MD, discusses the findings from a study of botensilimab plus bastilimab for the treatment of patients with recurrent platinum refractory/resistant ovarian cancer.
Carolina Frailty Index Score Validated in Ovarian Cancer
Carolina Frailty Index Score can effectively assess frailty status in women with ovarian cancer.
Dual Checkpoint Blockade With Neoadjuvant Chemo Shows Benefit in Ovarian Cancer
The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.
HRQOL Not Affected by Cytoreductive Surgery Plus HIPEC in Ovarian Cancer
According to Vadim Gushchin, MD, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of how it may impact a patient’s health-related quality of life.
Superior Efficacy Not Induced by the Addition of Olaparib to Cediranib in Advanced Endometrial Cancer
No statistically significant difference was seen with the combination of olaparib and cediranib compared to cediranib alone in patients with recurrent, metastatic or persistent endometrial cancer.
Previously Treated Patients With Vulvar Squamous Cell Carcinoma Have Durable Responses on Pembrolizumab
Data from the KEYNOTE-158 study, presented at the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, showed durable responses in heavily pretreated patients with vulvar squamous cell carcinoma regardless of their PD-L1 status.
Apatinib/Doxorubicin Combination Improves PFS Over Single Agent in Ovarian Cancer
The combination of apatinib and pegylated liposomal doxorubicin improved the progression-free survival for patients with platinum-resistant or refractory ovarian cancer in comparison to doxorubicin alone, according to data from the phase 2 APPROVE trial.
Enzalutamide/Chemotherapy Triplet Shows Promising Activity in Advanced or Recurrent Endometrioid Endometrial Cancer
Patients with advanced or recurrent endometrioid endometrial cancer had promising clinical outcomes following treatment with the combination of enzalutamide and carboplatin plus paclitaxel in the phase 2 ENPAC clinical trial.
Final Results of Niraparib Maintenance Shows Efficacy/Safety in Recurrent Ovarian Cancer
Ursula A. Matulonis, MD, discusses the effect of the PARP inhibitor niraparib on recurrent ovarian cancer.
PFS Benefit Sustained at 5-Year Follow-Up in SOLO-1 Trial of Maintenance Olaparib in Ovarian Cancer
After long-term follow-up, olaparib maintenance therapy demonstrated progression-free survival benefit in almost half of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients.
Niraparib Maintains PFS Improvement, But OS Data Are Limited in gBRCA+/- Ovarian Cancer
Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.
Both Germline, Somatic BRCA Mutations Benefit from Maintenance Olaparib in Platinum-Sensitive Relapsed Ovarian Cancer
Olaparib maintenance continues to show clinical activity in platinum-sensitive ovarian cancer, including in patients with somatic BRCA mutations and non-BRCA homologous recombination repair mutations.
Eribulin Induces Disease Control in Advanced/Recurrent Cervical Cancer
In a phase 2 trial treatment with eribulin led to disease control and a favorable safety profile among patients with recurrent or advanced cervical cancer.
Niraparib/Bevacizumab Combo Continues to Show Prolonged PFS in Patients With Advanced Ovarian Cancer
At the Society of Gynecological Oncology Virtual Annual Meeting on Women’s Cancer data from the phase II OVARIO study continued to show the progression free survival benefit for heavily pretreated patients with advanced ovarian cancer.
The Rationale of Maintenance With Durvalumab With or Without Olaparib in Patients With Endometrial Cancer
Shannon Westin, MD, MPH, FACOG, discusses the rationale of using durvalumab, a PD-L1 inhibitor, with or without olaparib.
Pembrolizumab/Lenvatinib Leads to Survival Benefit in Previously Treated Advanced Endometrial Cancer, Regardless of MMR Status
Progression-free survival and overall survival were improved with pembrolizumab and lenvatinib when compared with chemotherapy in patients with advanced endometrial cancer who had received prior platinum-based chemotherapy in the phase 3 Study-309/KEYNOTE-775 trial.
PD-1/PARP Triplet Regimen Shows Positive Clinical Activity, Tolerability in Ovarian Cancer
The addition of the investigational anti–PD-1 immunotherapy agent, dostarlimab, to niraparib and bevacizumab demonstrated positive antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.
Rucaparib Improves PFS in BRCA+ Relapsed Ovarian Cancer in Confirmatory ARIEL4 Trial
Compared with standard-of-care chemotherapy, treatment with the PARP inhibitor rucaparib led to a significant prolongation of progression-free survival and improved duration of response in patients with BRCA-mutated advanced, relapsed ovarian cancer, according to primary results from the phase 3 ARIEL4 trial.
Niraparib Shows Efficacy in Hard-to-Treat Patients With Newly Diagnosed Ovarian Cancer
Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.
Two Analyses Describe Patient Preferences for Maintenance Therapy in Ovarian Cancer
In an interview with Targeted Oncology, Charlotte Sun, DrPH, MPH, discussed the findings from 2 abstracts from the 2020 SGO Annual Meeting on patient preferences for maintenance therapy in ovarian cancer and how these findings can be applied to practice in the community oncology setting.
Targeted Agent Demonstrates Strong Activity in Uterine Serous Carcinoma
"Adavosertib demonstrated promising preliminary clinical activity in patients with unselected uterine serous cancer."
PARP Inhibitor Costs Give Patients With Ovarian Cancer Financial Toxicity
Ross F. Harrison, MD, discusses the out-of-pocket costs for patients with ovarian cancer receiving PARP inhibitor treatment.
Dostarlimab on the Road to Progress in dMMR Endometrial Cancer
“There are limited treatment options for women with advanced or recurrent endometrial cancer, and prognosis of these patients is poor. The results observed in the GARNET trial indicate the potential of dostarlimab to offer a new treatment option for women with this challenging disease.”
Cost-Effectiveness of Frontline PARP Inhibitor Maintenance in Advanced Ovarian Cancer
Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival over chemotherapy.
Veliparib Spotlighted for Antitumor Efficacy in Ovarian Cancer
In the phase III VELIA trial, the addition of veliparib to frontline induction chemotherapy expanded the number of complete responses and CA-125 responses in patients with high-grade serous ovarian cancer compared with chemotherapy alone, according to results from an exploratory analysis.
Vigil Immunotherapy Prolongs RFS as Frontline Maintenance Treatment in Ovarian Cancer
Relapse-free survival was prolonged in patients with stage III/IV ovarian cancer who received frontline maintenance treatment with Vigil immunotherapy compared with placebo. This was especially true for patients with BRCA1/2 wild-type disease, according to results from the phase II VITAL study.
2 Clarke Drive Cranbury, NJ 08512